199 related articles for article (PubMed ID: 34670546)
1. A multicenter, prospective study to observe the initial management of patients with differentiated thyroid cancer in China (DTCC study).
Ming J; Zhu JQ; Zhang H; Sun H; Wang J; Cheng RC; Xie L; Li XR; Tian W; Huang T
BMC Endocr Disord; 2021 Oct; 21(1):208. PubMed ID: 34670546
[TBL] [Abstract][Full Text] [Related]
2. Total thyroidectomy, without prophylactic central lymph node dissection, in the treatment of differentiated thyroid cancer. Clinical retrospective study on 221 cases.
Conzo G; Pasquali D; Bellastella G; Esposito K; Carella C; De Bellis A; Docimo G; Klain M; Iorio S; Napolitano S; Palazzo A; Pizza A; Sinisi AA; Zampella E; Bellastella A; Santini L
Endocrine; 2013 Oct; 44(2):419-25. PubMed ID: 23334946
[TBL] [Abstract][Full Text] [Related]
3. Radioactive iodine (RAI) therapy for distantly metastatic differentiated thyroid cancer (DTC) in juvenile versus adult patients.
Kammori M; Fukumori T; Sugishita Y; Hoshi M; Shimizu K; Yamada T
Endocr J; 2015; 62(12):1067-75. PubMed ID: 26424174
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes of low-dose and high-dose postoperative radioiodine therapy in patients with intermediate-risk differentiated thyroid cancer.
Jeong JH; Kong EJ; Jeong SY; Lee SW; Cho IH; Ah Chun K; Lee J; Ahn BC
Nucl Med Commun; 2017 Mar; 38(3):228-233. PubMed ID: 27984538
[TBL] [Abstract][Full Text] [Related]
5. Evaluating the 2015 American Thyroid Association Risk Stratification System in High-Risk Papillary and Follicular Thyroid Cancer Patients.
van Velsen EFS; Stegenga MT; van Kemenade FJ; Kam BLR; van Ginhoven TM; Visser WE; Peeters RP
Thyroid; 2019 Aug; 29(8):1073-1079. PubMed ID: 31140385
[No Abstract] [Full Text] [Related]
6. Real-World Performance of the American Thyroid Association Risk Estimates in Predicting 1-Year Differentiated Thyroid Cancer Outcomes: A Prospective Multicenter Study of 2000 Patients.
Grani G; Zatelli MC; Alfò M; Montesano T; Torlontano M; Morelli S; Deandrea M; Antonelli A; Francese C; Ceresini G; Orlandi F; Maniglia CA; Bruno R; Monti S; Santaguida MG; Repaci A; Tallini G; Fugazzola L; Monzani F; Giubbini R; Rossetto R; Mian C; Crescenzi A; Tumino D; Pagano L; Pezzullo L; Lombardi CP; Arvat E; Petrone L; Castagna MG; Spiazzi G; Salvatore D; Meringolo D; Solaroli E; Monari F; Magri F; Triggiani V; Castello R; Piazza C; Rossi R; Ferraro Petrillo U; Filetti S; Durante C
Thyroid; 2021 Feb; 31(2):264-271. PubMed ID: 32475305
[No Abstract] [Full Text] [Related]
7. Management of Retropharyngeal Lymph Node Metastases in Differentiated Thyroid Carcinoma.
Harries V; McGill M; Tuttle RM; Shaha AR; Wong RJ; Shah JP; Patel SG; Ganly I
Thyroid; 2020 May; 30(5):688-695. PubMed ID: 31910129
[No Abstract] [Full Text] [Related]
8. Therapeutic strategy for low-risk thyroid cancer in Kanaji Thyroid Hospital.
Kammori M; Fukumori T; Sugishita Y; Hoshi M; Yamada T
Endocr J; 2014; 61(1):1-12. PubMed ID: 24067543
[TBL] [Abstract][Full Text] [Related]
9. Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial.
Dehbi HM; Mallick U; Wadsley J; Newbold K; Harmer C; Hackshaw A
Lancet Diabetes Endocrinol; 2019 Jan; 7(1):44-51. PubMed ID: 30501974
[TBL] [Abstract][Full Text] [Related]
10. Postoperative radioactive iodine-131 ablation is not necessary among patients with intermediate-risk differentiated thyroid carcinoma: a population-based study.
Zhang H; Cai Y; Zheng L; Zhang Z; Jiang N
Hell J Nucl Med; 2017; 20(1):3-10. PubMed ID: 28315902
[TBL] [Abstract][Full Text] [Related]
11. The treatment of differentiated thyroid cancer in children: emphasis on surgical approach and radioactive iodine therapy.
Rivkees SA; Mazzaferri EL; Verburg FA; Reiners C; Luster M; Breuer CK; Dinauer CA; Udelsman R
Endocr Rev; 2011 Dec; 32(6):798-826. PubMed ID: 21880704
[TBL] [Abstract][Full Text] [Related]
12. Improved Survival After Multimodal Approach with
Wu D; Gomes Lima CJ; Moreau SL; Kulkarni K; Zeymo A; Burman KD; Wartofsky L; Van Nostrand D
Thyroid; 2019 Jul; 29(7):971-978. PubMed ID: 31017051
[No Abstract] [Full Text] [Related]
13. The Prospective Implementation of the 2015 ATA Guidelines and Modified ATA Recurrence Risk Stratification System for Treatment of Differentiated Thyroid Cancer in a Canadian Tertiary Care Referral Setting.
Wu J; Hu XY; Ghaznavi S; Kinnear S; Symonds CJ; Grundy P; Parkins VM; Sharma P; Lamb D; Khalil M; Hyrcza M; Chandarana SP; Pasieka JL; Harvey A; Warshawski J; Hart R; Deutschman M; Randall DR; Paschke R
Thyroid; 2022 Dec; 32(12):1509-1518. PubMed ID: 36226405
[No Abstract] [Full Text] [Related]
14. Outcomes after radioiodine ablation in patients with thyroid cancer: Long-term follow-up of a Chinese randomized clinicaltrial.
Dong P; Qu Y; Yang L; Xiao L; Huang R; Li L
Clin Endocrinol (Oxf); 2021 Nov; 95(5):782-789. PubMed ID: 34368999
[TBL] [Abstract][Full Text] [Related]
15. A Phase II Multi-Center, Non-Randomized, Parallel Group, Non-Inferiority Study to Compare the Efficacy of No Radioactive Iodine Remnant Ablation to Remnant Ablation Treatment in Low- to Intermediate-Risk of Papillary Thyroid Cancer: The MOREthyroid Trial Protocol.
Lee EK; Lee YJ; Park YJ; Moon JH; Yi KH; Kim KS; Lee JH; Cho SW; Joo J; Hwangbo Y; Go S; Park DJ
Endocrinol Metab (Seoul); 2020 Sep; 35(3):571-577. PubMed ID: 32981299
[TBL] [Abstract][Full Text] [Related]
16. Dynamic Risk Stratification for Predicting Recurrence in Patients with Differentiated Thyroid Cancer Treated Without Radioactive Iodine Remnant Ablation Therapy.
Park S; Kim WG; Song E; Oh HS; Kim M; Kwon H; Jeon MJ; Kim TY; Shong YK; Kim WB
Thyroid; 2017 Apr; 27(4):524-530. PubMed ID: 27869547
[TBL] [Abstract][Full Text] [Related]
17. Utility of Stimulated Thyroglobulin in Reclassifying Low Risk Thyroid Cancer Patients' Following Thyroidectomy and Radioactive Iodine Ablation: A 7-Year Prospective Trial.
Jammah AA; Masood A; Akkielah LA; Alhaddad S; Alhaddad MA; Alharbi M; Alguwaihes A; Alzahrani S
Front Endocrinol (Lausanne); 2020; 11():603432. PubMed ID: 33716951
[TBL] [Abstract][Full Text] [Related]
18. Response to Therapy Assessment in Intermediate-Risk Thyroid Cancer Patients: Is Thyroglobulin Stimulation Required?
Moreno I; Hirsch D; Duskin-Bitan H; Dicker-Cohen T; Shimon I; Robenshtok E
Thyroid; 2020 Jun; 30(6):863-870. PubMed ID: 31928205
[No Abstract] [Full Text] [Related]
19. Low-Risk Thyroid Cancer in Elderly: Total Thyroidectomy/RAI Predominates but Lacks Survival Advantage.
Zambeli-Ljepović A; Wang F; Dinan MA; Hyslop T; Roman SA; Sosa JA; Scheri RP
J Surg Res; 2019 Nov; 243():189-197. PubMed ID: 31185435
[TBL] [Abstract][Full Text] [Related]
20. Are Evidence-Based Guidelines Reflected in Clinical Practice? An Analysis of Prospectively Collected Data of the Italian Thyroid Cancer Observatory.
Lamartina L; Durante C; Lucisano G; Grani G; Bellantone R; Lombardi CP; Pontecorvi A; Arvat E; Felicetti F; Zatelli MC; Rossi R; Puxeddu E; Morelli S; Torlontano M; Crocetti U; Montesano T; Giubbini R; Orlandi F; Aimaretti G; Monzani F; Attard M; Francese C; Antonelli A; Limone P; Rossetto R; Fugazzola L; Meringolo D; Bruno R; Tumino S; Ceresini G; Centanni M; Monti S; Salvatore D; Spiazzi G; Mian C; Persani L; Barbaro D; Nicolucci A; Filetti S
Thyroid; 2017 Dec; 27(12):1490-1497. PubMed ID: 29020892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
